Evofem makes top-to-bottom cuts to save cash, slashing CEO pay by 40% and eliminating positions
Evofem makes top-to-bottom cuts to save cash, slashing CEO pay by 40% and eliminating positions
ntaylor
Tue, 03/21/2023 - 08:54
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon
ntaylor
Tue, 03/21/2023 - 06:26
Clario partners with Strados to offer respiratory tech for clinical trials
Clario partners with Strados to offer respiratory tech for clinical trials
jkeenan
Mon, 03/20/2023 - 22:16
Ruling on Elizabeth Holmes' prison delay, restitution to Theranos investors pushed back
Ruling on Elizabeth Holmes' prison delay, restitution to Theranos investors pushed back
apark
Mon, 03/20/2023 - 14:17
Gilead scoops up Nurix’s IRAK4 degrader for up to $445M, plucking first fruit grown from 2019 collab
Gilead scoops up Nurix’s IRAK4 degrader for up to $445M, plucking first fruit grown from 2019 collab
mbayer
Mon, 03/20/2023 - 12:12
Athenex's cash dries up as it faces clinical hold on cancer therapy in wake of patient death
Athenex's cash dries up as it faces clinical hold on cancer therapy in wake of patient death
gmasson
Mon, 03/20/2023 - 11:25
Illumina, Icahn trade jabs amid looming proxy fight over $8B Grail buy
Illumina, Icahn trade jabs amid looming proxy fight over $8B Grail buy
apark
Mon, 03/20/2023 - 10:27
BioNTech's cancer push continues, coughing up $200M for OncoC4's CTLA-4 antibody
BioNTech's cancer push continues, coughing up $200M for OncoC4's CTLA-4 antibody
mbayer
Mon, 03/20/2023 - 09:52
Karuna continues to build hype for schizophrenia drug with phase 3 data drop but investors not convinced
Karuna continues to build hype for schizophrenia drug with phase 3 data drop but investors not convinced
jwaldron
Mon, 03/20/2023 - 09:24
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
jwaldron
Mon, 03/20/2023 - 07:36
Takeda's $4B drug clears psoriasis in one-third of patients, laying down marker in bid to challenge BMS
Takeda's $4B drug clears psoriasis in one-third of patients, laying down marker in bid to challenge BMS
ntaylor
Mon, 03/20/2023 - 07:06
Biogen, Novartis deliver one-two punch to Sangamo, walking away from deals in quick succession
Biogen, Novartis deliver one-two punch to Sangamo, walking away from deals in quick succession
ntaylor
Mon, 03/20/2023 - 06:02
Cutiss sends skin cells to the International Space Station
Cutiss sends skin cells to the International Space Station
hfloersh
Mon, 03/20/2023 - 02:09
Syneos in AI-focused pact with Microsoft to speed up trials
Syneos in AI-focused pact with Microsoft to speed up trials
jkeenan
Sun, 03/19/2023 - 18:33
BD, Visby Medical snag updated FDA nods for women's health PCR tests
BD, Visby Medical snag updated FDA nods for women's health PCR tests
apark
Fri, 03/17/2023 - 15:21
Pear market: Digital therapeutics maker eyeing a sale in last-ditch money-saving move after layoffs, stock sale
Pear market: Digital therapeutics maker eyeing a sale in last-ditch money-saving move after layoffs, stock sale
apark
Fri, 03/17/2023 - 12:54
Return of the megaround: Is biotech back from the brink?
Return of the megaround: Is biotech back from the brink?
aarmstrong
Fri, 03/17/2023 - 11:40
Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile
Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile
mbayer
Fri, 03/17/2023 - 10:37
iRhythm COO steps down as $30M ‘business transformation’ plan kicks in
iRhythm COO steps down as $30M ‘business transformation’ plan kicks in
apark
Fri, 03/17/2023 - 10:13
Cash-strapped Acer sees menopause drug flunk phase 2 trial
Cash-strapped Acer sees menopause drug flunk phase 2 trial
jwaldron
Fri, 03/17/2023 - 10:12